← 홈

Antibody · 혈액암 (AML/ALL) · VEGF

36개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 36개
AntibodyHotRocheatApproved

Bevacizumab (Bevacizumab)

Colorectal Neoplasms · Recurrent Platinum-Sensitive Fallopian T

#RecurrentPlatinum-SensitiveFallo#Antibody#Approved#인기#항체+5
효능 ORR 100%임상시험 1131상태 RECRUITING
AntibodyRocheatApproved

bevacizumab [Avastin] (bevacizumab [Avastin])

Non-Squamous Non-Small Cell Lung Cancer · Pancreatic Cancer

#PancreaticCancer#Antibody#Approved#항체#면역항체+5
효능 ORR 83%임상시험 43상태 ACTIVE
AntibodyRochePreclinical

atezolizumab (Tecentriq, Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Preclinical#항체#면역항체+2
효능 ORR 88.7%임상시험 18상태 RECRUITING
AntibodystaleRochePhase 3

China-approved Bevacizumab (China-approved Bevacizumab)

Metastatic Colorectal Cancer (CRC) · Advanced Non-squamous Non-small-cell Lun

#AdvancedNon-squamousNon-small-ce#Antibody#Phase3#항체#면역항체+3
임상시험 2상태 ACTIVE
AntibodystaleRochePhase 2

Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel (Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleThe First Affiliated Hospital o…Phase 2

Adebrelimab Combined with Bevacizumab and Docetaxel (Adebrelimab Combined with Bevacizumab and Docetaxel)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Belinostat, carboplatin, paclitaxel and bevacizumab (Belinostat, carboplatin, paclitaxel and bevacizumab)

Non-Small-Cell Lung Carcinoma · Non-Small-Cell Lung Carcinoma

#Non-Small-CellLungCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 3

Bevacizumab + Pemetrexed (Bevacizumab + Pemetrexed)

Non-squamous Non-small Cell Lung Cancer · Non-squamous Non-small Cell Lung Cancer

#Non-squamousNon-smallCellLungCan#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Bevacizumab + Pemetrexed + Carboplatin (Bevacizumab + Pemetrexed + Carboplatin)

Non-squamous Non-small Cell Lung Cancer · Non-squamous Non-small Cell Lung Cancer

#Non-squamousNon-smallCellLungCan#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab + modified FOLFIRINOX (Bevacizumab + modified FOLFIRINOX)

Mucinous Ovarian Cancer; Fallopian Tube Cancer · Mucinous Ovarian Cancer

#MucinousOvarianCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab Biosimilar HLX04 (Bevacizumab Biosimilar HLX04)

Non-Squamous Non-Small Cell Lung Cancer · Non-Squamous Non-Small Cell Lung Cancer

#Non-SquamousNon-SmallCellLungCan#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab plus erlotinib (Bevacizumab plus erlotinib)

Carcinoma, Non-Small-Cell Lung; Brain Neoplasms · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab, Oxaliplatin, Pemetrexed (Bevacizumab, Oxaliplatin, Pemetrexed)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleImmunityBio, Inc.Phase 3

atezolizumab (Tecentriq, Carboplatin and paclitaxel plus atezolizumab and bevacizumab.)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleDizal PharmaceuticalsPhase 2

DZD9008 plus Bevacizumab (DZD9008 plus Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Docetaxel/Carboplatin/Bevacizumab/Erlotinib (Docetaxel/Carboplatin/Bevacizumab/Erlotinib)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleNational Cancer Center, KoreaPhase 2

Erlotinib plus Bevacizumab (Erlotinib plus Bevacizumab)

EGFR Positive Non-small Cell Lung Cancer · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab (Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleHunan Province Tumor HospitalPhase 2

IBI-323 combined with bevacizumab plus Platinum (IBI-323 combined with bevacizumab plus Platinum)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Bevacizumab Biosimilar Drug (MB02, MB02 (Bevacizumab Biosimilar Drug))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase3#항체#면역항체+2
효능 ORR 40.3%임상시험 1상태 ACTIVE

1 / 2 페이지

← 이전다음 →